ArticleEuropean journal of gastroenterology & hepatology2026
Associations between 12 insulin resistance surrogates with metabolic dysfunction-associated steatotic liver disease risk and all-cause mortality: data from the NHANES III (1988-1994).
Article in European journal of gastroenterology & hepatology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundMetabolic dysfunction-associated steatotic liver disease (MASLD) has been shown to be intimately linked to the presence of insulin resistance. This study aimed to comprehensively evaluate 12 insulin resistance surrogates in relation to MASLD risk and all-cause mortality, utilizing nationwide data from the National Health and Nutrition Examination Survey (NHANES) III (1988-1994).
methodsThis study analyzed 10 303 adults aged greater than or equal to 20 years from the NHANES III (1988-1994) cohort, identifying 2199 individuals with MASLD. The mortality data for this cohort were collected from the National Death Index. Twelve surrogate markers of insulin resistance were evaluated, including triglyceride-glucose (TyG) index, TyG-BMI, TyG-waist circumference, TyG-waist-to-height ratio, C-reactive protein-triglyceride-glucose index, atherogenic index of plasma (AIP), AIP-BMI, AIP-waist circumference, AIP-waist-to-height ratio, estimated glucose disposal rate (eGDR), metabolic score for insulin resistance, and homeostatic model assessment of insulin resistance (HOMA-IR). Statistical analyses employed logistic regression and Cox proportional hazards models to assess associations. Additionally, restricted cubic splines (RCSs) and Kaplan-Meier curves were utilized alongside subgroup and sensitivity analyses. Predictive performance was examined using receiver operating characteristic analysis and machine learning (XGBoost).
resultsAmong 10 303 participants, MASLD prevalence was 21.3%. In models that have undergone full adjustment, eGDR was negatively correlated with the risk of MASLD [odds ratio = 0.827, 95% confidence interval (CI): 0.780-0.878], while all other indices showed positive associations. In 2199 MASLD patients with 1015 deaths during follow-up, TyG-related indices, C-reactive protein-triglyceride-glucose index, and HOMA-IR were significant correlates with higher all-cause mortality, whereas eGDR was inversely correlated (hazard ratio = 0.887, 95% CI: 0.844-0.933). Two sensitive analyses further supported the overall results in the overall models. The RCS curve exhibited nonlinear dose-response relationships for several indices. XGBoost analyses identified eGDR as the strongest predictor of mortality among insulin resistance surrogates, second only to age.
conclusionMost insulin resistance surrogates were significantly associated with both MASLD risk and mortality, while eGDR emerged as a robust protective factor with superior predictive performance. These results emphasize the pivotal role of insulin resistance in MASLD and highlight eGDR as a promising noninvasive tool for stratifying risk and predicting adverse outcomes in clinical and public health settings.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.